What you will discover

Epistem will draw on their experience of conducting optical imaging studies in oncology, including in solid tumors and leukemia, using lentiviral-transduced disease models. Key topics include:

  • Lentiviral gene delivery
  • Optical imaging and quantification
  • Advantages and challenges of optical imaging
  • Examples of models in oncology
  • Visualizing tissue damage from radiation with optical imaging

Epistem is a UK biotechnology company. Its contract research division, which is presenting this webinar, has been operating for 16 years and delivers innovative pre-clinical research services with an in-depth specialist understanding of epithelial tissues.

During this webinar, they will outline their use of the Bruker In-Vivo Xtreme system in a number of cancer models, including leukemia, prostate cancer, and ovarian cancer. For example, Epistem offers models of acute myeloid leukemia and acute lymphoblastic leukemia.

Using the Xtreme system they can monitor disease progression and treatment efficacy over time in the animal with luminescent imaging, alongside the built-in X-ray function, fluorescent and radioisotopic imaging. Their method bypasses the problems associated with traditional graft techniques by using lentivirally-transduced human leukemic cell lines. The vector contains GFP and the firefly luciferase constructs, providing both fluorescent and bioluminescent signal the light produced reflects disease burden, and therefore can be used to track disease progression. They have used the technique to track both progress of solid tumors and metastasis in diseases including prostate and ovarian cancer.

As well as outlining their experience in these disease models, in this half-hour webinar Epistem will describe an approach to using optical imaging to explore the damaging effects of radiation on the gut. They will also cover the tricky matter of translating optical images into cell number and the strategies they have devised to tackle this.